/
Ophthalmology
Retinopathy of Prematurity
7
Pipeline Programs↗
11
Active Trials↗
7
Companies Involved↗
Retinopathy of Prematurity is an early-stage landscape with 7 programs across 7 companies. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical5
Phase 11
Phase 2
No programs
Approved
No programs
Analysis
Modality Breakdown
71%
Small molecule
5 of 7 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 7 pipeline programs.
Analysis
Trial Status
55
clinical trials
Completed32 · 58%
Recruiting9 · 16%
Unknown status7 · 13%
Terminated3 · 5%
Active, not recruiting1 · 2%
Not yet recruiting1 · 2%
Other2 · 4%
Clinical Trials
Trial Activity
55 trials
Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy: A Multicenter, Prospective, Randomized, Double-blind, Non-inferiority Clinical Trial
Recruiting·—·Preclinical·NCT06717412·146 enrolled
Intranasal Dexmedetomidine for Pain Management During Screening for Retinopathy of Prematurity
Recruiting·—·Phase 3·NCT06067958·30 enrolled
A Fatty Acids Study in Preventing Retinopathy of Prematurity
Completed·—·Phase 3·NCT02760472·90 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)